Teva and Alvotech have announced receipt of the US FDA approval to Selarsdi injection for use as an interchangeable with Stelara.

The updated recommendations also provide guidance on antirheumatic drug use through lactation and in male patients trying to ...

Pharma major Dr Reddy’s Laboratories Ltd’s consolidated net profit increased 21% in the fourth quarter ended March 31, 2025 ...

Biologics License Applications (BLAs) for three additional biosimilar candidates developed by Alvotech in partnership with Teva have been accepted for review by the FDA: AVT05, a proposed biosimilar ...

The partners also announced filing acceptance of U.S. Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab) and a BLA for AVT06, a proposed ...

Alvotech and Teva noted that they have three additional biosimilar candidates under review by the US regulator: a proposed biosimilar for Simponi (golimumab) and Simponi Aria (golimumab), AVT05 ...

There are currently four monoclonal antibodies available that are directed against TNF: infliximab, adalimumab, golimumab and certolizumab. All of these agents are efficacious in RA, with clinical ...

in 2012 and J&J’s Simponi (golimumab) in 2013. In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors ...

Golimumab (Simponi; Centocor), the first once-monthly, self-injectable TNF-specific mAb, was recently launched for RA, psoriatic arthritis and ankylosing spondylitis. Golimumab has the potential ...

He noted that in the longer term, J&J 's sales of Simponi Aria (golimumab) continue to grow in rheumatoid arthritis. The company has noted that s J&J has also filed sirukumab in the US and EU ...